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• Mild cognitive impairment (MCI) is a decline in cognitive
function to a greater extent than the natural aging process,
affecting memory, communication, and overall quality of life
•Reduced brain blood flow is strongly associated with
reduced cognitive function and neurodegenerative
diseases, of which is partially attributed to excessive
reactive oxygen species (ROS) production
•Previous studies have shown that mitoquinol mesylate, a
mitochondrial-targeted antioxidant, can improve endothelial
function and can scavenge ROS in healthy older adults,
however the impacts of mitoquinol mesylate intake on
vascular function in patients with MCI have not been
investigated
•In 2 study visits, 1 patient with MCI (male, age 84)
received mitoquinol mesylate (80 mg) or placebo (PL,
similar in appearance and taste) in a crossover study
design
•At each visit measurements of height, weight, body
composition, hand grip strength, HR, BP, brachial and
popliteal FMD, PWV, and cognitive function were
measured before and after mitoquinol and placebo intake
RESULTS
PURPOSE
•To examine the impacts of acute mitoquinol mesylate
intake on heart rate (HR), central and peripheral blood
pressures (BP), endothelial function (flow-mediated
dilation, FMD), arterial stiffness (pulse-wave velocity,
PWV), and cognitive function in patients with MCI
•It was hypothesized that acute mitoquinol intake would
improve vascular and cognitive function in patients with
MCI
Figure 1. Brachial artery FMD (%)
pre- and post-placebo and mitoquinol
intake (n=1)
Figure 2. Popliteal artery FMD
(%) pre- and post-placebo and
mitoquinol intake (n=1)
Figure 3. Carotid-to-radial PWV (m/s)
pre- and post-placebo and mitoquinol
intake (n=1)
Figure 4. Carotid-to-distal PWV
(m/s) pre- and post-placebo and
mitoquinol intake (n=1)
•Our preliminary results demonstrate that mitoquinol intake may
be a potentially useful therapeutic treatment for improving
vascular function via endothelial-dependent vasodilatory
mechanisms in patients with MCI
•However, this was a case study and investigation with a larger
sample size is warranted to fully elucidate these results
Flow-mediated dilation: measurement of
endothelial function using doppler ultrasound
This project was funded by the Fund for Undergraduate Scholarly Experience 
(FUSE) grant.
Table 2. Measurements of heart rate, central and peripheral blood pressures, and
vascular function pre- and post-placebo and mitoquinol intake
Pulse-wave velocity: measurement arterial
stiffness using applanation tonometry
Table 1. Participant characteristics at the placebo and mitoquinol intake visits (n=1)
Placebo (n=1) Mitoquinol (n=1) Δ
Age, y 84.0 84.0 0
Height, cm 164.0 164.0 0
Body mass, kg 83.4 81.2 2.2
BMI, kg/m^2 31.0 30.8 -0.2
Body fat, % 37.6 38.7 1.1
R handgrip strength, kg 34.0 34.0 0
L handgrip strength, kg 36.0 36.0 0
Placebo (n=1) Mitoquinol (n=1)
Pre Post Pre Post
RHR, bpm 81.0 82.0 81.0 81.0
Systolic BP, mmHg 138.0 147.0 140.0 140.0
Diastolic BP, mmHg 95.0 98.0 92.0 84.0
Central systolic BP, mmHg 123.0 128.0 139.0 130.0
Central diastolic BP, mmHg 94.0 94.0 92.0 84.0
Deceleration time, ms 524.0 641.0 665.0 411.0
Max dP/dt, mmHg/s 720.0 730.0 930.0 680.0
Peripheral PP, mmHg 48.0 56.0 41.0 35.0
Central PP, mmHg 47.0 46.0 34.0 36.0
Augmentation pressure, mmHg 6.0 2.0 12.0 17.0
AIx, % 18.0 26.3 26.3 37.0
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